ホームページ Cytoskeletal Signaling Cardiac Myosin

Cardiac Myosin

Cardiac Myosin製品

  • All (4)
  • Cardiac Myosin阻害剤 (2)
  • Cardiac Myosin活性剤(1)
  • Cardiac Myosinモジュレータ(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Eur Heart J, 2025, ehaf813
Circ Res, 2025, S1525-0016(25)00760-9.
Circulation, 2023, 147(25):1919-1932
S9948 Danicamtiv (MYK-491) Danicamtiv (MYK-491, SAR 440181) is a novel cardiac myosin activator that enhances cardiomyocyte contraction.
bioRxiv, 2024, 2024.10.09.617269
J Am Heart Assoc, 2023, 12(20):e030682
E4662 CK-586 CK-586(CK-4021586) is an inhibitor of cardiac myosin used to treat obstructive hypertrophic cardiomyopathy (oHCM). It effectively reduces left ventricular outflow tract obstruction (LVOTO) in a dose-dependent manner.
E1016 Aficamten (CK-274) Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractility in vitro and in vivo with an IC50 of 1.4 μM.
E4662 CK-586 CK-586(CK-4021586) is an inhibitor of cardiac myosin used to treat obstructive hypertrophic cardiomyopathy (oHCM). It effectively reduces left ventricular outflow tract obstruction (LVOTO) in a dose-dependent manner.
E1016 Aficamten (CK-274) Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractility in vitro and in vivo with an IC50 of 1.4 μM.
S9948 Danicamtiv (MYK-491) Danicamtiv (MYK-491, SAR 440181) is a novel cardiac myosin activator that enhances cardiomyocyte contraction.
bioRxiv, 2024, 2024.10.09.617269
J Am Heart Assoc, 2023, 12(20):e030682
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Eur Heart J, 2025, ehaf813
Circ Res, 2025, S1525-0016(25)00760-9.
Circulation, 2023, 147(25):1919-1932
united states